Bosentan reduces neuronal apoptosis following spinal cord ischemic reperfusion injury

S Gong,L Peng,B Yan,Q Dong,Z Seng,W Wang,J Lv,X He

DOI: https://doi.org/10.1038/sc.2013.133

2013-01-01

Spinal Cord

Abstract:Study design: Experimental study. Objectives: To investigate the effects of endothelin-receptor antagonist Bosentan on the spinal neural apoptosis in rats with ischemic reperfusion (IR) injury. Setting: Department of Neurosurgery, the Second Affiliated Hospital, Xi’an Jiaotong University School of Medcine, Xi’an, Shaanxi Province, China Methods: Sprague–Dawley Rats were randomly divided into two groups, saline (IRS, n =48) and Bosentan (IRB, n =48) treatment, respectively, when reperfused in 6 h, 12 h, 24 h, 3 days, 5 days and 7 days. Immunohistochemical staining was used to assess endothelin-1 (ET-1), endothelin receptor type A (ETR A ), endothelin receptor type B (ETR B ), Bcl-2, Bax, Caspase-8, Caspase-9 and Caspase-3 expression. ET-1 and its receptor in spinal cord tissue were evaluated by real-time PCR. Plasma ET-1 concentration was also detected using radioimmunoassay. Results: Compared with the group IRS, plasma concentration of ET-1 in group IRB was significantly increased at each time point ( P <0.05) and peaked at 24 h ( P <0.01). ETR B expression in group IRB was significantly higher than group IRS at each time point ( P <0.05) and peaked at day 3 ( P <0.01). The difference in the expression of ETR A was not statistically significant in the group IRS and IRB ( P >0.05). The apoptosis rate in group IRB was significantly decreased at each time point ( P <0.05). The protein expressions of Bcl-2, Bax, Caspase-8, Caspase-9 and Caspase-3 were significantly increased in response to Bosentan treatment after IR. Conclusion: These results suggest Bosentan decreases apoptosis rate after IR injury in the spinal cord, possibly through the ET-1-ETR B signaling pathway.